Status:
UNKNOWN
Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients With Antiphospholipid Syndrome.
Lead Sponsor:
Meir Medical Center
Conditions:
Antiphospholipid Syndrome
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic ...
Detailed Description
the investigators would like to assess the prevalence of Fabry in men and women aged 18-100 who were diagnosed with antiphospholipid syndrome in our departmental clinic in 2000-2017 It is very importa...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Antiphospholipid syndrome.
- able to read and sign inform concent
Exclusion
- • Fabry disease.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03384485
Start Date
February 1 2018
End Date
October 1 2018
Last Update
December 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meir Medical Center
Kfar Saba, Israel, 44281